PMID- 32399433
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230102
IS  - 2235-1795 (Print)
IS  - 1664-5553 (Electronic)
IS  - 1664-5553 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Apr
TI  - Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular 
      Carcinoma Patients Treated with Lenvatinib.
PG  - 193-206
LID - 10.1159/000504604 [doi]
AB  - BACKGROUND: Low skeletal muscle mass is significantly associated with severe 
      adverse events (AEs) from chemotherapy, and low tolerability leads to decreased 
      survival. We aimed to investigate whether body skeletal muscle mass is correlated 
      with tolerability and prognosis in patients with hepatocellular carcinoma (HCC) 
      treated with lenvatinib. METHODS: This multicenter, retrospective study was 
      conducted at five locations in Japan. We included 100 patients with HCC treated 
      with lenvatinib. Skeletal muscle mass was measured by computed tomography and 
      normalized for height in m(2) as skeletal muscle index (SMI). The assessment 
      criteria for low SMI were taken from the sarcopenia criteria of the Japan Society 
      of Hepatology. We investigated the influence of low SMI on drug withdrawal due to 
      severe AEs in the first 2 months and on time to treatment failure (TTF) and 
      overall survival (OS). RESULTS: The numbers of high- and low-SMI patients were 41 
      and 59, respectively. Those with severe AEs leading to withdraw in the high- and 
      low-SMI groups were 7 and 23, respectively. The low-SMI group had a higher 
      withdrawal rate than the high-SMI group (p = 0.042). The median TTF in the low- 
      and high-SMI groups was 139 and 230 days, respectively. The median OS in the low- 
      and high-SMI groups was 264 and 353 days, respectively. Patients in the low-SMI 
      group experienced significantly worse OS and TTF than those in the high-SMI group 
      (log-rank test for trend: TTF, p = 0.010; OS, p = 0.021). CONCLUSION: Decreased 
      skeletal muscle mass is associated with the occurrence of severe AEs and worse 
      TTF and OS. Skeletal muscle mass can be used as a predictive marker for 
      tolerability and prognosis to lenvatinib in patients with HCC.
CI  - Copyright (c) 2020 by S. Karger AG, Basel.
FAU - Uojima, Haruki
AU  - Uojima H
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
AD  - Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, 
      Japan.
FAU - Chuma, Makoto
AU  - Chuma M
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Tanaka, Yoshiaki
AU  - Tanaka Y
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Hidaka, Hisashi
AU  - Hidaka H
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
FAU - Nakazawa, Takahide
AU  - Nakazawa T
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
AD  - Nakazawa Medical Clinic, Sagamihara, Japan.
FAU - Iwabuchi, Shogo
AU  - Iwabuchi S
AD  - Department of Gastroenterology, Shonan Fujisawa Tokushukai Hospital, Fujisawa, 
      Japan.
FAU - Kobayashi, Satoshi
AU  - Kobayashi S
AD  - Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer 
      Center, Yokohama, Japan.
FAU - Hattori, Nobuhiro
AU  - Hattori N
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. 
      Marianna University School of Medicine, Kawasaki, Japan.
FAU - Ogushi, Katsuaki
AU  - Ogushi K
AD  - Gastroenterological Center, Yokohama City University Medical Center, Yokohama, 
      Japan.
FAU - Morimoto, Manabu
AU  - Morimoto M
AD  - Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer 
      Center, Yokohama, Japan.
FAU - Kagawa, Tatehiro
AU  - Kagawa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara, Japan.
FAU - Tanaka, Katsuaki
AU  - Tanaka K
AD  - Department of Gastroenterology, Japanese Red Cross Hadano Hospital, Hadano, 
      Japan.
FAU - Kako, Makoto
AU  - Kako M
AD  - Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, 
      Japan.
FAU - Koizumi, Wasaburo
AU  - Koizumi W
AD  - Department of Gastroenterology, Internal Medicine, Kitasato University School of 
      Medicine, Sagamihara, Japan.
LA  - eng
PT  - Journal Article
DEP - 20191206
PL  - Switzerland
TA  - Liver Cancer
JT  - Liver cancer
JID - 101597993
EIN - Liver Cancer. 2022 Oct 4;11(6):581. PMID: 36589731
PMC - PMC7206580
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
OT  - Skeletal muscle mass
COIS- The authors have no conflicts of interest.
EDAT- 2020/05/14 06:00
MHDA- 2020/05/14 06:01
PMCR- 2019/12/06
CRDT- 2020/05/14 06:00
PHST- 2019/08/17 00:00 [received]
PHST- 2019/11/04 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/05/14 06:01 [medline]
PHST- 2019/12/06 00:00 [pmc-release]
AID - lic-0009-0193 [pii]
AID - 10.1159/000504604 [doi]
PST - ppublish
SO  - Liver Cancer. 2020 Apr;9(2):193-206. doi: 10.1159/000504604. Epub 2019 Dec 6.